SUPRATHERAPEUTIC UNFRACTIONATED HEPARIN ANTI-XA LEVELS DUE TO TREATMENT-DOSE ENOXAPARIN EXPOSURE

被引：0
|
作者：
Anthes, Ananth
Providence, Sarah
Wilmer, Carrie [1 ]
Zhao, Xinhua [2 ]
Aspinall, Sherrie [3 ]
机构：
[1] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
[2] Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA
[3] VA Ctr Medicat Safety, Pharm Benefits Management Serv, Hines, IL USA
来源：
CRITICAL CARE MEDICINE | 2022年 / 50卷 / 01期
关键词：
D O I：
10.1097/01.ccm.0000810088.32788.fb
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
941
引用
收藏
页码：467 / 467
页数：1
相关论文
共 50 条
  • [21] Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents
    Smahi, Motalib
    De Pooter, Neila
    Hollestelle, Martine J.
    Toulon, Pierre
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) : 2613 - 2621
  • [22] Reassessment of dextran sulfate in anti-Xa assay for unfractionated heparin laboratory monitoring
    Hardy, Michael
    Cabo, Julien
    Deliege, Antoine
    Douxfils, Jonathan
    Gouin-Thibault, Isabelle
    Lecompte, Thomas
    Mullier, Francois
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (08)
  • [23] ENOXAPARIN PROPHYLAXIS DOSE ADJUSTED BY ANTI-XA TROUGH LEVELS IN CRITICALLY INJURED TRAUMA PATIENTS
    Roth, Jennifer
    Vaughan, Nathan
    Alaidroos, Imaan
    Rainey, Evan Elizabeth
    Roden-Foreman, Jacob
    Powers, Mark
    Garrett, John
    Foreman, Michael
    [J]. CRITICAL CARE MEDICINE, 2018, 46 (01) : 773 - 773
  • [24] Lack of correlation between aPTT, anti-Xa activity, and heparin dose in children receiving therapeutic doses of unfractionated heparin (UFH)
    Kuhle, S
    Eulmeskian, P
    Massicotte, MP
    Vegh, P
    Persaud, K
    Kavanagh, B
    Mitchell, L
    [J]. PEDIATRIC RESEARCH, 2003, 53 (04) : 284A - 284A
  • [25] Anti-Xa concentration better than activated partial thromboplastin time for the monitoring of unfractionated heparin treatment
    Moumneh, T.
    Mallecian, Y.
    Calmes, A.
    Lacour, E.
    Roy, P. M.
    [J]. EUROPEAN HEART JOURNAL, 2017, 38 : 360 - 361
  • [26] Achievement of Therapeutic Anti-Xa Levels in a Proven Heparin-Resistant Patient Through the Use of Nontraditional High-Dose Enoxaparin
    Krajewski, Kristin C.
    Smith, Kelly
    Conwall, Katherine
    Krajewski, Michael P., Jr.
    [J]. ANNALS OF PHARMACOTHERAPY, 2015, 49 (01) : 130 - 134
  • [27] Challenges of converting to anti-Xa monitoring of IV unfractionated heparin in an oral factor Xa inhibitor era
    Pham, Van Q.
    Chan, Linh L.
    Crumpler, Walter L.
    Wang, Anita
    Jacobson, Alan K.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2019, 47 (04) : 611 - 611
  • [28] DISCORDANT ANTI-XA AND PTT LEVELS DURING UNFRACTIONATED HEPARIN THERAPY AND INCREASED CLINICAL RISK FOR ADVERSE EVENTS
    Myers, Lauren
    Barker, Andrew
    Wagener, Brant
    [J]. ANESTHESIA AND ANALGESIA, 2019, 128 : 218 - 221
  • [29] ACHIEVEMENT OF PROPHYLACTIC ANTI-XA LEVELS IN TRAUMA PATIENTS RECEIVING ENOXAPARIN
    Meadows, Evan
    Partlow, Karen
    Rubertus, Matthew
    Quick, Valerie
    Davis, John
    Flannagan, Molly
    Griffin, Mary Lewis
    [J]. CRITICAL CARE MEDICINE, 2024, 52
  • [30] A comprehensive approach towards automated anti-IIa and anti-Xa testing of unfractionated heparin
    Shaklee, P. N.
    Reinke, K. J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 360 - 360
12345